16. クロウ・深瀬症候群 Crow-Fukase syndrome Clinical trials / Disease details
臨床試験数 : 13 / 薬物数 : 14 - (DrugBank : 7) / 標的遺伝子数 : 4 - 標的パスウェイ数 : 75
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | ChiCTR2200056637 | 2022-02-08 | 2022-02-09 | A multicenter, open and exploratory clinical study of pomadomide combined with dexamethasone in the treatment of newly diagnosed POEMS syndrome | A multicenter, open and exploratory clinical study of pomadomide combined with dexamethasone in the treatment of newly diagnosed POEMS syndrome | Multiple myeloma | Pd:Pomadomide combined with dexamethasone in the treatment of patients with newly diagnosed POEMS syndrome ; | Qingdao Municipal Hospital | NULL | Recruiting | 18 | 100 | Both | Pd:30; | Phase 4 | China |
2 | NCT02921893 (ClinicalTrials.gov) | October 31, 2016 | 26/9/2016 | Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients With POEMS Syndrome | Ixazomib, Lenalidomide, and Dexamethasone for Patients With POEMS Syndrome | Plasmacytoma;POEMS Syndrome | Drug: Dexamethasone;Drug: Ixazomib Citrate;Drug: Lenalidomide;Other: Questionnaire Administration | Mayo Clinic | National Cancer Institute (NCI) | Active, not recruiting | 18 Years | N/A | All | 21 | Early Phase 1 | United States |
3 | NCT01816620 (ClinicalTrials.gov) | March 2014 | 14/3/2013 | Study to Evaluate Lenalidomide Plus Dexamethasone in Patients With Newly Diagnosed POEMS Syndrome | An Open-label Phase II Study to Determine the Efficacy and Safety of Lenalidomide Plus Dexamethasone (LDex) in Patients With Newly Diagnosed POEMS Syndrome | POEMS Syndrome | Drug: Lenalidomide, Dexamethasone | Peking Union Medical College Hospital | Celgene Corporation | Completed | 18 Years | N/A | All | 41 | Phase 2 | China |
4 | NCT01639898 (ClinicalTrials.gov) | July 2012 | 5/7/2012 | POEMS Syndrome Treatment With Lenalidomide | Phase II Trial With Lenalidomide-Dexamethasone Combination in the Treatment of POEMS Syndrome. | POEMS Syndrome | Drug: Lenalidomide and dexamethasone | University Hospital, Limoges | Ministry of Health, France;Celgene Corporation | Completed | 18 Years | N/A | All | 51 | Phase 2 | France |
5 | NCT00971685 (ClinicalTrials.gov) | July 2009 | 3/9/2009 | The Treatment of Lenalidomide in Patients With POEMS Syndrome | Evaluation of Efficacy and Safety of Lenalidomide (Revlimid®) in Patients With POEMS Syndrome | POEMS Syndrome | Drug: Lenalidomide and dexamethasone | Istituto Clinico Humanitas | NULL | Recruiting | 18 Years | N/A | Both | 16 | Phase 2 | Italy |